How Biogen’s Tysabri and Zinbryta Performed in 1Q17


Dec. 4 2020, Updated 10:51 a.m. ET

Tysabri’s growth trends

In 1Q17, Biogen (BIIB) saw an increased demand for Tysabri, both in the United States and in international markets. Prescribers have been increasingly favoring Tysabri’s benefit-risk profile. Increased physician confidence may further boost the drug’s sales volumes in future quarters.

Data from the Tysabri observational program have demonstrated the benefits of early treatment with the drug in treatment-naïve MS (multiple sclerosis) patients. The program also showed that a higher benefit accrued to those patients who continue with Tysabri and don’t switch to other therapies in the longer term.

If these trends result in increased demand for Tysabri in future quarters, it may have a positive impact on Biogen stock as well as the Health Care Select Sector SPDR ETF (XLV). Biogen makes up about 2.3% of XLV’s total portfolio holdings.

Article continues below advertisement

Revenue growth

In 1Q17, Tysabri reported revenues close to $545.0 million, which is a YoY (year-over-year) rise of around 14.0%. The drug earned revenues of $306.0 million in the US market and the remaining $239.0 million from international markets.

Tysabri’s international market revenues were higher by about $45.0 million in 1Q17 since Biogen entered into an agreement with the pricing committee of the Italian Medicines Agency.

Tysabri is expected to be affected by Ocrevus, Roche Holdings’ (RHHBY) newly approved MS therapy. In spite of being an MS market leader, Biogen faces stiff competition from other MS players such as Sanofi (SNY) and Novartis (NVS).


Biogen and AbbVie are both involved in launching Zinbryta, another MS therapy, in US and international markets.

In the next part of this series, we’ll look at the growth trends for Spinraza, Biogen’s SMA (spinal muscular atrophy) drug.


More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.